advises the European Commission), 4 an Independent Scottish review committee 5 and the New Zealand Accident Compensation Corporation, 6 issuing cautions regarding use of transvaginal mesh for the management of pelvic organ prolapse. This has led to women not only questioning the efficacy and safety of transvaginal meshes for prolapse but also questioning the highly effective mid-urethral slings for the management of stress urinary incontinence, as well as the competence and trustworthiness of us as clinicians. It is imperative that pelvic floor surgeons take a leadership role that ensures the mistakes of the past are not revisited.
From 2003 transvaginal mesh was introduced into treatment pathways for pelvic organ prolapse without adequate evaluation of their safety or efficacy. 1 Initial confidence in these products was extrapolated from the success of synthetic mesh for hernia repair, 7 sacral colpopexy for vault prolapse 8 and mid-urethral slings for urinary stress incontinence. 9 There was no evidence from comparative trials of either the safety or the efficacy of any of the transvaginal mesh products until seven years after they were brought into treatment pathways. 10 By this time is had become evident that, due to the properties and function of the vagina, mesh had unpredicted complications when used in the vagina, specifically pain and dyspareunia due to mesh contraction and high rates of mesh exposure.
1,11
After transvaginal mesh placement, one in ten women undergo reoperation for mesh exposure. 12 The number who undergo reoperation for, or live with, chronic pain is poorly defined. We do know that pain and/or dyspareunia were the leading causes of adverse events reported to the FDA and that in a series reporting on re-intervention after transvaginal mesh, pain and dyspareunia are the leading indicators for reoperation at a rate higher than mesh exposure. 13 It has been argued that a proportion of the blame for this high complication rate can be assigned to the fact that transvaginal meshes were so quickly up-taken by pelvic floor surgeons regardless of their surgical experience, volume or procedure-specific training. 14 However, high-volume, experienced surgeons who sought out procedure-specific training have also reported high complication rates with transvaginal meshes. Maher et al. 15 reported a reop- mesh and quality of life and sexual outcomes are not improved.
There is limited evidence that the use of absorbable mesh may decrease recurrent prolapse on examination and there is insufficient evidence as to whether biological grafts add benefit to native tissue repairs.
The 2016 Cochrane Review on anterior compartment 17 prolapse found that synthetic mesh reduces awareness of recurrent prolapse, objective prolapse and reoperation for recurrent prolapse, but results in higher overall reoperation rates for either prolapse, stress urinary incontinence or mesh exposure and higher rates of recurrent prolapse in both the apical and posterior compartments. In retrospective studies the risk-benefit profile is similar for recurrent anterior wall prolapse but with a higher reported rate of mesh erosion for recurrent prolapse. 18 It is also known that in the posterior compartment neither mesh nor grafts improve anatomical or functional outcomes.
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For utero-vaginal prolapse, the data is not supportive of hysterectomy and concomitant vaginal repair with mesh, due to the high rates of mesh erosion associated with this combination of operations 20 and it remains undefined as to whether there is a role for vaginal mesh in uterine preservation surgery. We are awaiting the publication of the first randomized controlled trial (RCT) on this subject from the Pelvic Floor Disorders Network.
21
For apical prolapse there is evidence that transvaginal mesh does not improve anatomical or functional outcomes and the mesh exposure rate is 18% with 10% requiring surgery to correct the exposure. There is currently level three (non-comparative) evidence reporting outcomes after placement in women. Altman et al. 22 reported a multi-centre prospective case series evaluating 207 women with apical prolapse undergoing Uphold pelvic floor system repair and reported a subjective success rate of 90% at one year. The reoperation rate for mesh exposure was 1.3%. Vu et al. 23 As a group, our collective unfounded enthusiasm for transvaginal meshes resulted in loss of trust from women. We cannot, in good faith, vouch for the safety or efficacy of any of the currently available transvaginal meshes. We have alternative procedures to offer women that are supported by robust evidence of both safety and efficacy. Until comparative data confirms the safety and efficacy of the currently available transvaginal meshes, it would be prudent if these products were utilised under the auspices of the local ethics committee. This not only protects women from risk of harm but also protect us, the surgeons, from repeating mistakes of the past.
It is through this process that evidence defining the role for transvaginal mesh in reconstructive pelvic surgery will be established. If favourable new data becomes available regarding new innovations, treatment pathways can be modified to reflect the evidence.
